Search

Your search keyword '"Schlossman, Robert L."' showing total 432 results
Start Over Author "Schlossman, Robert L." Publication Year Range Last 50 years
432 results on '"Schlossman, Robert L."'

2. Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling

Author

Ho, Matthew, Chen, Tianzeng, Liu, Jiye, Dowling, Paul, Hideshima, Teru, Zhang, Li, Morelli, Eugenio, Camci-Unal, Gulden, Wu, Xinchen, Tai, Yu-Tzu, Wen, Kenneth, Samur, Mehmet, Schlossman, Robert L., Mazitschek, Ralph, Kavanagh, Emma L., Lindsay, Sinéad, Harada, Takeshi, McCann, Amanda, Anderson, Kenneth C., O’Gorman, Peter, and Bianchi, Giada

Published
2020
Full Text
View/download PDF

3. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

Author

Holstein, Sarah A, Jung, Sin-Ho, Richardson, Paul G, Hofmeister, Craig C, Hurd, David D, Hassoun, Hani, Giralt, Sergio, Stadtmauer, Edward A, Weisdorf, Daniel J, Vij, Ravi, Moreb, Jan S, Callander, Natalie S, van Besien, Koen, Gentile, Teresa G, Isola, Luis, Maziarz, Richard T, Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H, Rodriguez, Cesar, McClune, Brian, Schlossman, Robert L, Smith, Scott E, Hars, Vera, Owzar, Kouros, Jiang, Chen, Boyd, Molly, Schultz, Chelsea, Wilson, Marcia, Hari, Parameswaran, Pasquini, Marcelo C, Horowitz, Mary M, Shea, Thomas C, Devine, Steven M, Linker, Charles, Anderson, Kenneth C, and McCarthy, Philip L

Published
2017
Full Text
View/download PDF

4. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant

Author

Mouhieddine, Tarek H., Sperling, Adam S., Redd, Robert, Park, Jihye, Leventhal, Matthew, Gibson, Christopher J., Manier, Salomon, Nassar, Amin H., Capelletti, Marzia, Huynh, Daisy, Bustoros, Mark, Sklavenitis-Pistofidis, Romanos, Tahri, Sabrin, Hornburg, Kalvis, Dumke, Henry, Itani, Muhieddine M., Boehner, Cody J., Liu, Chia-Jen, AlDubayan, Saud H., Reardon, Brendan, Van Allen, Eliezer M., Keats, Jonathan J., Stewart, Chip, Mehr, Shaadi, Auclair, Daniel, Schlossman, Robert L., Munshi, Nikhil C., Anderson, Kenneth C., Steensma, David P., Laubach, Jacob P., Richardson, Paul G., Ritz, Jerome, Ebert, Benjamin L., Soiffer, Robert J., Trippa, Lorenzo, Getz, Gad, Neuberg, Donna S., and Ghobrial, Irene M.

Published
2020
Full Text
View/download PDF

5. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Author

San-Miguel, Jesús F, Hungria, Vania T M, Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios A, Elghandour, Ashraf, Jedrzejczak, Wieslaw W, Günther, Andreas, Nakorn, Thanyaphong N, Siritanaratkul, Noppadol, Schlossman, Robert L, Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae H, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Binlich, Florence, and Richardson, Paul G

Published
2016
Full Text
View/download PDF

6. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Author

Richardson, Paul G., Hungria, Vânia T.M., Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios Athanasios, Elghandour, Ashraf, Jedrzejczak, Wieslaw W., Guenther, Andreas, Nakorn, Thanyaphong Na, Siritanaratkul, Noppadol, Schlossman, Robert L., Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Corrado, Claudia, Binlich, Florence, and San-Miguel, Jesús F.

Published
2016
Full Text
View/download PDF

7. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Author

San-Miguel, Jesús F, Hungria, Vânia T M, Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios Athanasios, Elghandour, Ashraf, Jedrzejczak, Wieslaw Wiktor, Günther, Andreas, Nakorn, Thanyaphong Na, Siritanaratkul, Noppadol, Corradini, Paolo, Chuncharunee, Suporn, Lee, Je-Jung, Schlossman, Robert L, Shelekhova, Tatiana, Yong, Kwee, Tan, Daryl, Numbenjapon, Tontanai, Cavenagh, Jamie D, Hou, Jian, LeBlanc, Richard, Nahi, Hareth, Qiu, Lugui, Salwender, Hans, Pulini, Stefano, Moreau, Philippe, Warzocha, Krzysztof, White, Darrell, Bladé, Joan, Chen, WenMing, de la Rubia, Javier, Gimsing, Peter, Lonial, Sagar, Kaufman, Jonathan L, Ocio, Enrique M, Veskovski, Ljupco, Sohn, Sang Kyun, Wang, Ming-Chung, Lee, Jae Hoon, Einsele, Hermann, Sopala, Monika, Corrado, Claudia, Bengoudifa, Bourras-Rezki, Binlich, Florence, and Richardson, Paul G

Published
2014
Full Text
View/download PDF

8. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Author

Richardson, Paul G., Xie, Wanling, Jagannath, Sundar, Jakubowiak, Andrzej, Lonial, Sagar, Raje, Noopur S., Alsina, Melissa, Ghobrial, Irene M., Schlossman, Robert L., Munshi, Nikhil C., Mazumder, Amitabha, Vesole, David H., Kaufman, Jonathan L., Colson, Kathleen, McKenney, Mary, Lunde, Laura E., Feather, John, Maglio, Michelle E., Warren, Diane, Francis, Dixil, Hideshima, Teru, Knight, Robert, Esseltine, Dixie-Lee, Mitsiades, Constantine S., Weller, Edie, and Anderson, Kenneth C.

Published
2014
Full Text
View/download PDF

10. Multiple Myeloma

Author

Schlossman, Robert L., Chang, Alfred E., editor, Hayes, Daniel F., editor, Pass, Harvey I., editor, Stone, Richard M., editor, Ganz, Patricia A., editor, Kinsella, Timothy J., editor, Schiller, Joan H., editor, and Strecher, Victor J., editor

Published
2006
Full Text
View/download PDF

11. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Author

Richardson, Paul G., primary, Jacobus, Susanna J., additional, Weller, Edie A., additional, Hassoun, Hani, additional, Lonial, Sagar, additional, Raje, Noopur S., additional, Medvedova, Eva, additional, McCarthy, Philip L., additional, Libby, Edward N., additional, Voorhees, Peter M., additional, Orlowski, Robert Z., additional, Anderson, Larry D., additional, Zonder, Jeffrey A., additional, Milner, Carter P., additional, Gasparetto, Cristina, additional, Agha, Mounzer E., additional, Khan, Abdullah M., additional, Hurd, David D., additional, Gowin, Krisstina, additional, Kamble, Rammurti T., additional, Jagannath, Sundar, additional, Nathwani, Nitya, additional, Alsina, Melissa, additional, Cornell, R. Frank, additional, Hashmi, Hamza, additional, Campagnaro, Erica L., additional, Andreescu, Astrid C., additional, Gentile, Teresa, additional, Liedtke, Michaela, additional, Godby, Kelly N., additional, Cohen, Adam D., additional, Openshaw, Thomas H., additional, Pasquini, Marcelo C., additional, Giralt, Sergio A., additional, Kaufman, Jonathan L., additional, Yee, Andrew J., additional, Scott, Emma, additional, Torka, Pallawi, additional, Foley, Amy, additional, Fulciniti, Mariateresa, additional, Hebert, Kyle, additional, Samur, Mehmet K., additional, Masone, Kelly, additional, Maglio, Michelle E., additional, Zeytoonjian, Andrea A., additional, Nadeem, Omar, additional, Schlossman, Robert L., additional, Laubach, Jacob P., additional, Paba-Prada, Claudia, additional, Ghobrial, Irene M., additional, Perrot, Aurore, additional, Moreau, Philippe, additional, Avet-Loiseau, Hervé, additional, Attal, Michel, additional, Anderson, Kenneth C., additional, and Munshi, Nikhil C., additional

Published
2022
Full Text
View/download PDF

13. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial

Author

San‐Miguel, Jesús F., Hungria, Vania T. M., Yoon, Sung‐Soo, Beksac, Meral, Dimopoulos, Meletios A., Elghandour, Ashraf, Jedrzejczak, Wieslaw W., Guenther, Andreas, Na Nakorn, Thanyaphong, Siritanaratkul, Noppadol, Schlossman, Robert L., Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae‐Hoon, Einsele, Hermann, Salwender, Hans, Sopala, Monika, Redhu, Suman, Paul, Sofia, Corrado, Claudia, and Richardson, Paul G.

Published
2017
Full Text
View/download PDF

15. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Author

Jakubowiak, Andrzej J., Griffith, Kent A., Reece, Donna E., Hofmeister, Craig C., Lonial, Sagar, Zimmerman, Todd M., Campagnaro, Erica L., Schlossman, Robert L., Laubach, Jacob P., Raje, Noopur S., Anderson, Tara, Mietzel, Melissa A., Harvey, Colleen K., Wear, Sandra M., Barrickman, Jennifer C., Tendler, Craig L., Esseltine, Dixie-Lee, Kelley, Susan L., Kaminski, Mark S., Anderson, Kenneth C., and Richardson, Paul G.

Published
2011
Full Text
View/download PDF

16. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Author

Richardson, Paul G., Weller, Edie, Lonial, Sagar, Jakubowiak, Andrzej J., Jagannath, Sundar, Raje, Noopur S., Avigan, David E., Xie, Wanling, Ghobrial, Irene M., Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Vesole, David H., Joyce, Robin, Kaufman, Jonathan L., Doss, Deborah, Warren, Diane L., Lunde, Laura E., Kaster, Sarah, DeLaney, Carol, Hideshima, Teru, Mitsiades, Constantine S., Knight, Robert, Esseltine, Dixie-Lee, and Anderson, Kenneth C.

Published
2010
Full Text
View/download PDF

18. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

Author

Yee, Andrew J., Hari, Parameswaran, Marcheselli, Raffaella, Mahindra, Anuj K., Cirstea, Diana D., Scullen, Tyler A., Burke, Jill N., Rodig, Scott J., Hideshima, Teru, Laubach, Jacob P., Ghobrial, Irene M., Schlossman, Robert L., Munshi, Nikhil C., Anderson, Kenneth C., Weller, Edie A., Richardson, Paul G., and Raje, Noopur S.

Published
2014
Full Text
View/download PDF

20. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins

Author

Shirasaki, Ryosuke, primary, Matthews, Geoffrey M., additional, Gandolfi, Sara, additional, de Matos Simoes, Ricardo, additional, Buckley, Dennis L., additional, Raja Vora, Joseline, additional, Sievers, Quinlan L., additional, Brüggenthies, Johanna B., additional, Dashevsky, Olga, additional, Poarch, Haley, additional, Tang, Huihui, additional, Bariteau, Megan A., additional, Sheffer, Michal, additional, Hu, Yiguo, additional, Downey-Kopyscinski, Sondra L., additional, Hengeveld, Paul J., additional, Glassner, Brian J., additional, Dhimolea, Eugen, additional, Ott, Christopher J., additional, Zhang, Tinghu, additional, Kwiatkowski, Nicholas P., additional, Laubach, Jacob P., additional, Schlossman, Robert L., additional, Richardson, Paul G., additional, Culhane, Aedin C., additional, Groen, Richard W.J., additional, Fischer, Eric S., additional, Vazquez, Francisca, additional, Tsherniak, Aviad, additional, Hahn, William C., additional, Levy, Joan, additional, Auclair, Daniel, additional, Licht, Jonathan D., additional, Keats, Jonathan J., additional, Boise, Lawrence H., additional, Ebert, Benjamin L., additional, Bradner, James E., additional, Gray, Nathanael S., additional, and Mitsiades, Constantine S., additional

Published
2021
Full Text
View/download PDF

22. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

Author

Richardson, Paul G., Laubach, Jacob P., Schlossman, Robert L., Ghobrial, Irene M., Redman, Katherine C., Mckenney, Mary, Warren, Diane, Noonan, Kimberly, Lunde, Laura, Doss, Deborah, Colson, Kathleen, Hideshima, Teru, Mitsiades, Constantine, Munshi, Nikhil C., and Anderson, Kenneth C.

Published
2012
Full Text
View/download PDF

28. Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling

Author

Ho, Matthew, Chen, Tianzeng, Liu, Jiye, Dowling, Paul, Hideshima, Teru, Zhang, Li, Morelli, Eugenio, Camci-Unal, Gulden, Wu, Xinchen, Tai, Yu-Tzu, Wen, Kenneth, Samur, Mehmet, Schlossman, Robert L., Mazitschek, Ralph, Kavanagh, Emma L., Lindsay, Sinéad, Harada, Takeshi, McCann, Amanda, Anderson, Kenneth C., O’Gorman, Peter, Bianchi, Giada, Ho, Matthew, Chen, Tianzeng, Liu, Jiye, Dowling, Paul, Hideshima, Teru, Zhang, Li, Morelli, Eugenio, Camci-Unal, Gulden, Wu, Xinchen, Tai, Yu-Tzu, Wen, Kenneth, Samur, Mehmet, Schlossman, Robert L., Mazitschek, Ralph, Kavanagh, Emma L., Lindsay, Sinéad, Harada, Takeshi, McCann, Amanda, Anderson, Kenneth C., O’Gorman, Peter, and Bianchi, Giada

Abstract

Multiple myeloma (MM) is an incurable cancer that derives pro-survival/proliferative signals from the bone marrow (BM) niche. Novel agents targeting not only cancer cells, but also the BM-niche have shown the greatest activity in MM. Histone deacetylases (HDACs) are therapeutic targets in MM and we previously showed that HDAC3 inhibition decreases MM proliferation both alone and in co-culture with bone marrow stromal cells (BMSC). In this study, we investigate the effects of HDAC3 targeting in BMSCs. Using both BMSC lines as well as patient-derived BMSCs, we show that HDAC3 expression in BMSCs can be induced by co-culture with MM cells. Knock-out (KO), knock-down (KD), and pharmacologic inhibition of HDAC3 in BMSCs results in decreased MM cell proliferation; including in autologous cultures of patient MM cells with BMSCs. We identified both quantitative and qualitative changes in exosomes and exosomal miRNA, as well as inhibition of IL-6 trans-signaling, as molecular mechanisms mediating anti-MM activity. Furthermore, we show that HDAC3-KD in BM endothelial cells decreases neoangiogenesis, consistent with a broad effect of HDAC3 targeting in the BM-niche. Our results therefore support the clinical development of HDAC3 inhibitors based not only on their direct anti-MM effects, but also their modulation of the BM microenvironment.

Published
2019

33. A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Author

Laubach, Jacob P., Liu, Chia-Jen, Raje, Noopur S., Yee, Andrew J., Armand, Philippe, Schlossman, Robert L., Rosenblatt, Jacalyn, Hedlund, Jacquelyn, Martin, Michael, Reynolds, Craig, Shain, Kenneth H., Zackon, Ira, Stampleman, Laura, Henrick, Patrick, Rivotto, Bradley, Hornburg, Kalvis T.V., Dumke, Henry J., Chuma, Stacey, Savell, Alexandra, Handisides, Damian R., Kroll, Stew, Anderson, Kenneth C., Richardson, Paul G., and Ghobrial, Irene M.

Subjects
Aged, 80 and over, Male, Kaplan-Meier Estimate, Middle Aged, Article, Bortezomib, Treatment Outcome, Drug Resistance, Neoplasm, Nitroimidazoles, Antineoplastic Combined Chemotherapy Protocols, Retreatment, Disease Progression, Humans, Female, Phosphoramide Mustards, Neoplasm Recurrence, Local, Multiple Myeloma, Aged, Neoplasm Staging
Abstract

INTRODUCTION. The presence of hypoxia in the diseased bone marrow presents a new therapeutic target for multiple myeloma (MM). Evofosfamide (formerly TH-302) is a 2-nitroimidazole prodrug of the DNA alkylator bromo-isophosphoramide mustard that is selectively activated under hypoxia. A phase 1/2 study investigating evofosfamide in combination with dexamethasone (EvoD) and in combination with bortezomib and dexamethasone (EvoBorD) in relapsed/refractory MM. EXPERIMENTAL DESIGN: 59 patients initiated therapy, 31 received EvoD and 28 received EvoBorD. Pts were heavily pre-treated with a median number of prior therapies of 7 (range: 2–15). All had previously received bortezomib and immunomodulators. The maximum tolerated dose (MTD), treatment toxicity, and efficacy were determined. RESULTS: The MTD was established at 340 mg/m(2) Evo+D with dose limiting mucositis at higher doses. For EVOBorD, no patient had a dose limiting toxicity and the recommended phase 2 dose was established at 340 mg/m(2). The most common ≥ Gr 3 adverse events were thrombocytopenia (25 patients), anemia (24 patients), neutropenia (15 patients) and leukopenia (9 patients). Skin toxicity was reported in 42 (71%). Responses included 1 VGPR, 3 PR, 2 MR, 20 SD and 4 PD for EvoD and 1 CR, 2 PR, 1 MR, 18 SD and 5 PD for EvoBorD. Disease stabilization was observed in over 80% and this was reflective of the prolonged overall survival of 11.2 months. CONCLUSIONS: Evofosfamide can be administered at 340 mg/m(2) twice a week with or without bortezomib. Clinical activity has been noted in patients with heavily pre-treated relapsed refractory MM.

Published
2018

34. Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

Author

O'Donnell, Elizabeth K., primary, Laubach, Jacob P., additional, Yee, Andrew J., additional, Redd, Robert, additional, Huff, Carol Ann, additional, Basile, Frank, additional, Wade, Philip M., additional, Paba-Prada, Claudia E., additional, Ghobrial, Irene M., additional, Schlossman, Robert L., additional, Burke, Jill N., additional, Harrington, Cynthia C., additional, Lively, Kathleen J., additional, Lyons, Hannah, additional, Munshi, Nikhil C., additional, Anderson, Kenneth C., additional, Richardson, Paul G., additional, and Raje, Noopur S., additional

Published
2019
Full Text
View/download PDF

35. Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study

Author

Noga, Stephen J, primary, Rifkin, Robert M., additional, Manda, Sudhir, additional, Birhiray, Ruemu Ejedafeta, additional, Lyons, Roger M., additional, Whidden, Presley, additional, Schlossman, Robert L., additional, Wang, Bingxia, additional, and Boccia, Ralph V., additional

Published
2019
Full Text
View/download PDF

36. Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Author

Shirasaki, Ryosuke, primary, Gandolfi, Sara, primary, De Matos Simoes, Ricardo, primary, Matthews, Geoffrey M, primary, Buckley, Dennis, primary, Raja, Joseline, primary, Sievers, Quinlan L, primary, Dashevsky, Olga, primary, Poarch, Haley, primary, Tang, Huihui, primary, Bariteau, Megan, primary, Sheffer, Michal, primary, Downey-Kopyscinski, Sondra L., primary, Hengeveld, Paul, primary, Glassner, Brian, primary, Dhimolea, Eugen, primary, Ott, Christopher J., primary, Zhang, Tinghu, primary, Kwiatkowski, Nicholas P, primary, Laubach, Jacob P., primary, Schlossman, Robert L., primary, Richardson, Paul G., primary, Culhane, Aedin, primary, Groen, Richard W.J., primary, Fischer, Eric, primary, Ebert, Benjamin L., primary, Vazquez, Francisca, primary, Tsherniak, Aviad, primary, Hahn, William C., primary, Levy, Joan, primary, Auclair, Daniel, primary, Licht, Jonathan D., primary, Keats, Jonathan J, primary, Boise, Lawrence H., primary, Bradner, James, primary, Gray, Nathanael, primary, and Mitsiades, Constantine S., primary

Published
2019
Full Text
View/download PDF

37. Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazomib-Based Induction: Results from the US MM-6 Study in the Real World (RW) Setting

Author

Rifkin, Robert M., primary, Manda, Sudhir, additional, Noga, Stephen J, additional, Yimer, Habte A, additional, Girnius, Saulius K., additional, Birhiray, Ruemu Ejedafeta, additional, Yasenchak, Christopher A., additional, Lyons, Roger M., additional, Whidden, Presley, additional, Schlossman, Robert L., additional, Wang, Bingxia, additional, and Boccia, Ralph V., additional

Published
2019
Full Text
View/download PDF

38. Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling

Author

Ho, Matthew, primary, Chen, Tianzeng, additional, Liu, Jiye, additional, Dowling, Paul, additional, Hideshima, Teru, additional, Zhang, Li, additional, Morelli, Eugenio, additional, Camci-Unal, Gulden, additional, Wu, Xinchen, additional, Tai, Yu-Tzu, additional, Wen, Kenneth, additional, Samur, Mehmet, additional, Schlossman, Robert L., additional, Mazitschek, Ralph, additional, Kavanagh, Emma L., additional, Lindsay, Sinéad, additional, Harada, Takeshi, additional, McCann, Amanda, additional, Anderson, Kenneth C., additional, O’Gorman, Peter, additional, and Bianchi, Giada, additional

Published
2019
Full Text
View/download PDF

39. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Author

Laubach, Jacob P., primary, Liu, Chia-Jen, additional, Raje, Noopur S., additional, Yee, Andrew J., additional, Armand, Philippe, additional, Schlossman, Robert L., additional, Rosenblatt, Jacalyn, additional, Hedlund, Jacquelyn, additional, Martin, Michael, additional, Reynolds, Craig, additional, Shain, Kenneth H., additional, Zackon, Ira, additional, Stampleman, Laura, additional, Henrick, Patrick, additional, Rivotto, Bradley, additional, Hornburg, Kalvis T.V., additional, Dumke, Henry J., additional, Chuma, Stacey, additional, Savell, Alexandra, additional, Handisides, Damian R., additional, Kroll, Stew, additional, Anderson, Kenneth C., additional, Richardson, Paul G., additional, and Ghobrial, Irene M., additional

Published
2019
Full Text
View/download PDF

43. Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Author

Bustoros, Mark, primary, Liu, Chia-jen, additional, Reyes, Kaitlen, additional, Hornburg, Kalvis, additional, Guimond, Kathleen, additional, Styles, Rachel, additional, Savell, Alexandra, additional, Berrios, Brianna, additional, Warren, Diane, additional, Dumke, Henry, additional, Rivotto, Bradley, additional, Henrick, Patrick, additional, Scranton, Emily, additional, Leblebjian, Houry, additional, Meid, Kirsten, additional, Schlossman, Robert L., additional, Munshi, Nikhil, additional, Laubach, Jacob, additional, Anderson, Kenneth C., additional, Richardson, Paul, additional, and Ghobrial, Irene M., additional

Published
2018
Full Text
View/download PDF

44. The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome

Author

Mouhieddine, Tarek H, primary, Park, Jihye, additional, Redd, Robert A., additional, Gibson, Christopher J., additional, Manier, Salomon, additional, Nassar, Amin H, additional, Capelletti, Marzia, additional, Huynh, Daisy, additional, Bustoros, Mark, additional, Sklavenitis-Pistofidis, Romanos, additional, Hornburg, Kalvis, additional, Dumke, Henry, additional, Itani, Muhieddine M, additional, Boehner, Cody J, additional, Liu, Chia-Jen, additional, AlDubayan, Saud H, additional, Reardon, Brendan, additional, Van Allen, Eliezer, additional, Auclair, Daniel, additional, Schlossman, Robert L., additional, Munshi, Nikhil, additional, Anderson, Kenneth, additional, Steensma, David P., additional, Laubach, Jacob, additional, Richardson, Paul, additional, Ritz, Jerome, additional, Ebert, Benjamin L., additional, Soiffer, Robert J., additional, Neuberg, Donna S, additional, and Ghobrial, Irene M., additional

Published
2018
Full Text
View/download PDF

45. CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Author

Shirasaki, Ryosuke, primary, Gandolfi, Sara, additional, De Matos Simoes, Ricardo, additional, Matthews, Geoffrey, additional, Buckley, Dennis, additional, Dashevsky, Olga, additional, Downey-Kopyscinski, Sondra L., additional, Tang, Huihui, additional, Sheffer, Michal, additional, Dhimolea, Eugen, additional, Glassner, Brian, additional, Bariteau, Megan, additional, Sorrell, Jeffrey, additional, Bruggenthies, Johanna B, additional, Sievers, Quinlan, additional, Poarch, Haley, additional, Kwiatkowski, Nicholas P, additional, Zhang, Tinghu, additional, Laubach, Jacob, additional, Schlossman, Robert L., additional, Richardson, Paul, additional, Culhane, Aedin, additional, Groen, Richard WJ, additional, Fischer, Eric S., additional, Vazquez, Francisca, additional, Tsherniak, Aviad, additional, Hahn, William C., additional, Levy, Joan, additional, Auclair, Daniel, additional, Licht, Jonathan D., additional, Keats, Jonathan J, additional, Boise, Lawrence H., additional, Ebert, Benjamin L., additional, Bradner, James, additional, Gray, Nathanae, additional, and Mitsiades, Constantine S., additional

Published
2018
Full Text
View/download PDF

46. Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Author

Liu, Chia-jen, primary, Ghobrial, Irene M., additional, Bustoros, Mark, additional, Reyes, Kaitlen, additional, Hornburg, Kalvis, additional, Badros, Ashraf Z., additional, Vredenburgh, James J., additional, Boruchov, Adam, additional, Matous, Jeffrey V, additional, Caola, Aaron, additional, Rivotto, Bradley, additional, Savell, Alexandra, additional, Henrick, Patrick, additional, Paba-Prada, Claudia E., additional, Schlossman, Robert L., additional, Laubach, Jacob, additional, Rosenblatt, Jacalyn, additional, Yee, Andrew J, additional, Nadeem, Omar, additional, Maegawa, Rodrigo O., additional, Jakubowiak, Andrzej, additional, Usmani, Saad Z., additional, Bhutani, Manisha, additional, Cappuccio, Joseph, additional, Berrios, Brianna, additional, Noonan, Kimberly, additional, Zavidij, Oksana, additional, Mouhieddine, Tarek H, additional, Boehner, Cody J, additional, Neuse, Carl-Jannes, additional, Salem, Karma Ziad, additional, Reidy, Mairead, additional, Park, Jihye, additional, Agius, Michael, additional, Rahmat, Mahshid, additional, Manier, Salomon, additional, Bhutani, Divaya, additional, Zonder, Jeffrey A, additional, Munshi, Nikhil, additional, Auclair, Daniel, additional, Anderson, Kenneth, additional, and Richardson, Paul, additional

Published
2018
Full Text
View/download PDF

47. Abstract 2954: Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential

Author

Mouhieddine, Tarek H., primary, Park, Jihye, additional, Redd, Robert, additional, Gibson, Christopher J., additional, Manier, Salomon, additional, Nassar, Amin, additional, Hornburg, Kalvis, additional, Capelletti, Marzia, additional, Huynh, Daisy, additional, Pistofidis, Romanos Sklavenitits, additional, Bustoros, Mark W., additional, AlDubayan, Saud H., additional, Reardon, Brendan, additional, Boehner, Cody J., additional, Dumke, Henry, additional, Lui, Chia-Jen, additional, Schott, Darlys, additional, Allen, Eliezer M. Van, additional, Schlossman, Robert L., additional, Munshi, Nikhil C., additional, Anderson, Kenneth C., additional, Steensma, David P., additional, Laubach, Jacob P., additional, Richardson, Paul G., additional, Ritz, Jerome, additional, Ebert, Benjamin L., additional, Soiffer, Robert J., additional, Neuberg, Donna, additional, and Ghobrial, Irene M., additional

Published
2018
Full Text
View/download PDF

48. A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Author

Yee, Andrew Jenho, primary, Laubach, Jacob, additional, Campagnaro, Erica Leigh, additional, Lipe, Brea, additional, Nadeem, Omar, additional, Cole, Craig, additional, O'Donnell, Elizabeth, additional, Schlossman, Robert L., additional, Bianchi, Giada, additional, Branagan, Andrew Robert, additional, Shapiro, Samantha J., additional, Harrington, Cynthia C., additional, Burke, Jill N., additional, Gammon, Marilyn T., additional, Lively, Kathleen J., additional, Thorburn, Cassandra Ann, additional, Mann, Mason L., additional, Lohr, Jens Guenter, additional, Richardson, Paul G., additional, and Raje, Noopur S., additional

Published
2018
Full Text
View/download PDF

50. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

Author

O'Donnell, Elizabeth K., primary, Laubach, Jacob P., additional, Yee, Andrew J., additional, Chen, Tianqi, additional, Huff, Carol Ann, additional, Basile, Frank G., additional, Wade, Philip M., additional, Paba-Prada, Claudia E., additional, Ghobrial, Irene M., additional, Schlossman, Robert L., additional, Burke, Jill N., additional, Harrington, Cynthia C., additional, Lively, Kathleen J., additional, Lyons, Hannah F., additional, Munshi, Nikhil C., additional, Anderson, Kenneth C., additional, Trippa, Lorenzo, additional, Richardson, Paul G., additional, and Raje, Noopur S., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results